BioLargo, Inc.

BioLargo, Inc.

OOTC:BLGO
0.07
USD
+0.00
(-0.07%)
-0.06EPS
36.42MMarket Cap
Nov 18Next Earn

Total Valuation

USD

As of June 30, 2026, BioLargo, Inc. carries a market capitalization of 36.42M, placing it among publicly traded companies globally. Its enterprise value stands at 39.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap36.42M
Enterprise Value39.75M

Important Dates

BioLargo, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

Earnings Date11/18/2026

Share Statistics

As of June 30, 2026, BioLargo, Inc. has 320.88M shares outstanding.

Shares Outstanding320.88M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 8.78, and the price-to-book ratio stands at -19.67.

PS Ratio8.78
PB Ratio-19.67
P/TBV Ratio-19.31
P/FCF Ratio-3.39
P/OCF Ratio-3.47

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 9.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 39.75M versus a market cap of 36.42M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.74

Financial Position

As of June 30, 2026, BioLargo, Inc. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -234.21, indicating conservative leverage, while an interest coverage ratio of -21.94 demonstrates limited ability to service its debt obligations.

Current Ratio0.73
Quick Ratio0.61
Debt / Equity-234.21
Debt / EBITDA-0.36
Interest Coverage-21.94

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -151.14, reflecting losses generated across the asset base. The company generates approximately 89,736.26 in revenue per employee across its workforce of 45.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.56 indicates how many times BioLargo, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-151.14
Revenue Per Employee89,736.26
Employee Count45.50
Inventory Turnover6.56

Stock Price Statistics

USD

As of the close on November 16, 2026, BioLargo, Inc.'s stock has declined approximately 56.59% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.12.

52-Week Price Change-56.59%
50-Day Moving Average0.08
200-Day Moving Average0.12

Income Statement

USD

Over the twelve months ended June 30, 2026, BioLargo, Inc. generated 4.08M in revenue and converted that into -14.48M in net income, yielding earnings per share of -0.06. EBITDA reached -17.66M, while operating income came in at -14.22M.

Revenue4.08M
Gross Profit1.63M
Operating Income-14.22M
Pretax Income-18.79M
Net Income-14.48M
EBITDA-17.66M
EBIT-18.12M
Earnings Per Share (EPS)-0.06

Balance Sheet

USD

As of June 30, 2026, BioLargo, Inc. holds 2.19M in cash and equivalents against 6.39M in total debt, resulting in a net debt position of 2.92M. Total book value stands at -1.85M, with working capital of -1.27M providing operational flexibility.

Cash & Cash Equivalents2.19M
Total Debt6.39M
Net Debt2.92M
Equity (Book Value)-1.85M
Book Value Per Share-0.01
Working Capital-1.27M

Cash Flow

USD

BioLargo, Inc. produced -10.32M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -238,000.00 in capital expenditures, free cash flow totaled -10.56M - equivalent to -0.03 per share.

Operating Cash Flow-10.32M
Capital Expenditures-238,000.00
Free Cash Flow-10.56M
FCF Per Share-0.03

Margins

Over the twelve months ended June 30, 2026, BioLargo, Inc. posted a gross margin of 40.00, reflecting its pricing power and cost economics. The operating margin of -348.35 and net profit margin of -354.76 provide insight into operational efficiency.

Gross Margin40.00
Operating Margin-348.35
Pretax Margin-460.23
Profit Margin-354.76
EBITDA Margin-432.50

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -29.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.69, meaning BioLargo, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-24.69
FCF Yield-29.46

Stock Splits

BioLargo, Inc.'s most recent stock split took place on March 21, 2007 with a 25:1 split ratio.

Last Split Date3/21/2007
Split Ratio25:1

Scores

As of June 30, 2026, BioLargo, Inc. has an Altman Z-Score of -39.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-39.46